|
Feb 13
|
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data
|
|
Feb 13
|
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?
|
|
Feb 13
|
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?
|
|
Feb 12
|
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial
|
|
Feb 12
|
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
|
|
Feb 12
|
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
|
|
Feb 11
|
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
|
|
Jul 29
|
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
|
|
Jun 24
|
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
|
|
May 22
|
Industry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16%
|
|
May 9
|
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 9
|
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
|
|
May 9
|
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
|
|
May 9
|
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
|
|
May 2
|
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
May 1
|
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
|
|
Apr 24
|
Actym Therapeutics Appoints Thomas Smart as CEO
|
|
Apr 15
|
BTIG Research Predicts Over 118% Rally for These 3 Stocks
|
|
Apr 12
|
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
|
|
Apr 9
|
Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
|